Xencor, Inc. (NASDAQ: XNCR) announced that Phase 1 study results of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE